

What is claimed is:

1. A substantially pure ARP1 nucleic acid molecule, comprising substantially the nucleotide sequence shown as SEQ ID NO:1.
- 5 2. A substantially pure ARP1 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 722 to 1026 of SEQ ID NO:1.
3. The substantially pure ARP1 nucleic acid molecule of claim 2, comprising at least 15 contiguous
10 nucleotides of nucleotides 722 to 1026 of SEQ ID NO:1.
4. A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:
 - (a) contacting a sample from said individual
15 with an ARP1 nucleic acid molecule comprising at least 10 contiguous nucleotides of SEQ ID NO:1;
 - (b) determining a test expression level of ARP1 RNA in said sample; and
 - (c) comparing said test expression level to a
20 non-neoplastic control expression level of ARP1 RNA,
wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.

T032484-03301

5. The method of claim 4, wherein said sample comprises prostate tissue.

6. The method of claim 4, wherein said sample is selected from the group consisting of blood, urine and
5 semen.

7. The method of claim 4, wherein said ARP1 nucleic acid molecule is 15 to 18 nucleotides in length.

8. A method for treating or reducing the severity of a prostate neoplastic condition in an
10 individual, comprising administering to said individual an ARP1 regulatory agent.

9. A substantially pure ARP2 nucleic acid molecule, comprising substantially the nucleotide sequence shown as SEQ ID NO:2.

15 10. A substantially pure ARP2 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 1128 to 4509 of SEQ ID NO:2.

11. The substantially pure ARP2 nucleic acid molecule of claim 10, comprising at least 15 contiguous
20 nucleotides of nucleotides 1128 to 4509 of SEQ ID NO:2.

00001817-032201

(a) contacting a sample from said individual
5 with an ARP2 nucleic acid molecule comprising at least 10
contiguous nucleotides of nucleotides 1128 to 4509 of SEQ
ID NO:2;

10 (c) comparing said test expression level to a
non-neoplastic control expression level of ARP2 RNA,
wherein an altered test expression level as
compared to said control expression level indicates the
presence of a prostate neoplastic condition in said
15 individual.

14. The method of claim 12, wherein said sample is selected from the group consisting of blood, urine and semen.

16. A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP2 regulatory agent.

17.

5

10

—

15

RNA in said sample; and

20

25

23. The method of claim 20, wherein said ARP3
5 nucleic acid molecule is 15 to 18 nucleotides in length.

25. The substantially pure ARP3 polypeptide of
10 claim 24, comprising the amino acid sequence shown as SEQ
ID NO:5.

15 27. A binding agent, comprising a molecule
that selectively binds an ARP3 polypeptide having at
least 45% amino acid identity with SEQ ID NO:5.

28. The binding agent of claim 27, wherein said binding agent is an antibody.

(a) contacting a specimen from said individual
5 with the binding agent of claim 27;

(c) comparing said test expression level to a non-neoplastic control expression level of ARP3 polypeptide,

15 30. The method of claim 29, wherein said
specimen comprises prostate tissue.

20 32. The method of claim 29, wherein said
binding agent that selectively binds said ARP3
polypeptide is an antibody.

33. A method for treating or reducing the severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP3 regulatory agent.

5 35. The substantially pure ARP4 nucleic acid molecule of claim 34, which encodes the amino acid sequence shown as SEQ ID NO:7.

37. A substantially pure ARP4 nucleic acid molecule, comprising at least 10 contiguous nucleotides of nucleotides 821 to 1940 of SEQ ID NO:6.

39. A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

(b) determining a test expression level of ARP4 RNA in said sample; and

(c) comparing said test expression level to a non-neoplastic control expression level of ARP4 RNA, wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.

40. The method of claim 39, wherein said sample comprises prostate tissue.

41. The method of claim 39, wherein said sample is selected from the group consisting of blood, urine and semen.

42. The method of claim 39, wherein said ARP4 nucleic acid molecule is 15 to 18 nucleotides in length.

43. A substantially pure ARP4 polypeptide, comprising an amino acid sequence having at least 50% amino acid identity with SEQ ID NO:7.

44. The substantially pure ARP4 polypeptide of claim 43, comprising the amino acid sequence shown as SEQ ID NO:7.

45. A substantially pure ARP4 polypeptide fragment, comprising at least eight contiguous amino acids of SEQ ID NO:7.

46. A binding agent, comprising a molecule that selectively binds an ARP4 polypeptide having at least 50% amino acid identity with SEQ ID NO:7.

00001813 000004

binding and
is an ant
method of d
a prostate
sing:
acting a s
gent of cla
termining a
a said spec
paring said
control expres
an altered
control expres
ate neoplas
method of
prostate t
method of
d from the
men.
method of
selectivel
antibody.

5

W

A

10

15

S

20

D

hod for tr
 te neoplas
 ng adminis
 gent.

substantially
 a nucleic
 ing at lea

substantial
 , which en
 Q ID NO:9.

substantial
 , comprisi
 .

substantially
 at least
 o 1276 of

substantial
 , comprisi
 otides 565

5

10

stantially
comprising

15

20

(a) contacting a sample from said individual
5 with an ARP5 nucleic acid molecule comprising at least 10
contiguous nucleotides of SEQ ID NO:8;

(c) comparing said test expression level to a non-neoplastic control expression level of ARP5 RNA, wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said individual.

60. The method of claim 58, wherein said sample is selected from the group consisting of blood, urine and semen.

62. A substantially pure ARP5 polypeptide, comprising substantially an amino acid sequence having at least 40% amino acid identity with SEQ ID NO:9.

63. The substantially pure ARP5 polypeptide of claim 62, comprising the amino acid sequence shown as SEQ ID NO:9.

64. A substantially pure ARP5 polypeptide
5 fragment, comprising at least eight contiguous amino acids of SEQ ID NO:9.

65. A binding agent, comprising a molecule that selectively binds an ARP5 polypeptide having at least 40% amino acid identity with SEQ ID NO:9.

10 66. The binding agent of claim 65, wherein said binding agent is an antibody.

67. A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

15 (a) contacting a specimen from said individual with the binding agent of claim 65;

(b) determining a test expression level of ARP5 polypeptide in said specimen; and

(c) comparing said test expression level to a
20 non-neoplastic control expression level of ARP5 polypeptide,

wherein an altered test expression level as compared to said control expression level indicates the presence of a prostate neoplastic condition in said
25 individual.

00021812-032801

68. The method of claim 67, wherein said specimen comprises prostate tissue.

69. The method of claim 67, wherein said specimen is selected from the group consisting of blood,
5 serum, urine and semen.

70. The method of claim 67, wherein said binding agent that selectively binds said ARP5 polypeptide is an antibody.

71. A method for treating or reducing the
10 severity of a prostate neoplastic condition in an individual, comprising administering to said individual an ARP5 regulatory agent.

09821812-032301